NL301185I2 - Combinatie van daunorubicine en cytarabine - Google Patents
Combinatie van daunorubicine en cytarabineInfo
- Publication number
- NL301185I2 NL301185I2 NL301185C NL301185C NL301185I2 NL 301185 I2 NL301185 I2 NL 301185I2 NL 301185 C NL301185 C NL 301185C NL 301185 C NL301185 C NL 301185C NL 301185 I2 NL301185 I2 NL 301185I2
- Authority
- NL
- Netherlands
- Prior art keywords
- cytarabine
- daunorubicin
- combination
- Prior art date
Links
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 title 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 title 1
- 229960000684 cytarabine Drugs 0.000 title 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 title 1
- 229960000975 daunorubicin Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90177207P | 2007-02-16 | 2007-02-16 | |
| US96519607P | 2007-08-17 | 2007-08-17 | |
| EP08730048.9A EP2120568B1 (en) | 2007-02-16 | 2008-02-15 | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders |
| PCT/US2008/054168 WO2008101214A2 (en) | 2007-02-16 | 2008-02-15 | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL301185I2 true NL301185I2 (nl) | 2022-07-21 |
Family
ID=39690832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL301185C NL301185I2 (nl) | 2007-02-16 | 2022-07-05 | Combinatie van daunorubicine en cytarabine |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8092828B2 (OSRAM) |
| EP (3) | EP3300601B1 (OSRAM) |
| JP (1) | JP5314600B2 (OSRAM) |
| KR (2) | KR20100014441A (OSRAM) |
| CN (1) | CN105998046A (OSRAM) |
| AU (1) | AU2008216083B2 (OSRAM) |
| CA (1) | CA2678332C (OSRAM) |
| CY (1) | CY1119631T1 (OSRAM) |
| DK (2) | DK2120568T3 (OSRAM) |
| ES (2) | ES2650167T3 (OSRAM) |
| FR (1) | FR22C1034I2 (OSRAM) |
| HR (1) | HRP20220428T3 (OSRAM) |
| HU (2) | HUE058334T2 (OSRAM) |
| LU (1) | LUC00271I2 (OSRAM) |
| NL (1) | NL301185I2 (OSRAM) |
| NO (2) | NO2120568T3 (OSRAM) |
| PL (2) | PL2120568T3 (OSRAM) |
| PT (2) | PT2120568T (OSRAM) |
| SI (1) | SI3300601T1 (OSRAM) |
| WO (1) | WO2008101214A2 (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100075937A1 (en) * | 2008-09-24 | 2010-03-25 | Hollis-Eden Pharmaceuticals, Inc. | Patient populations and treatment methods |
| SI2768484T1 (sl) * | 2011-10-21 | 2019-12-31 | Jazz Pharmaceuticals Research Llc | Liofilizirani liposomi |
| US20140154304A1 (en) * | 2012-11-30 | 2014-06-05 | Boehringer Ingelheim International Gmbh | Combination therapy with volasertib |
| WO2015127172A1 (en) * | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2015127173A1 (en) * | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| MX2018005771A (es) | 2015-11-11 | 2019-03-14 | Celator Pharmaceuticals Inc | Ensayos y metodos para seleccionar un regimen de tratamiento para un sujeto con leucemia. |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| WO2019023873A1 (zh) * | 2017-07-31 | 2019-02-07 | 江苏竞诺择生物医药科技有限公司 | 一种用于治疗造血系统增殖性疾病的纳米脂质微粒组合物及药用组合物 |
| CA3114002A1 (en) * | 2018-09-25 | 2020-04-02 | Celator Pharmaceuticals, Inc. | Low-intensity treatment of hematological disorders |
| EP3891207B1 (en) | 2018-12-04 | 2022-11-02 | TIEN, Der-Yang | Stereocomplexes for the delivery of anti-cancer agents |
| EP3930702A1 (en) | 2019-03-01 | 2022-01-05 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11980636B2 (en) | 2020-11-18 | 2024-05-14 | Jazz Pharmaceuticals Ireland Limited | Treatment of hematological disorders |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| WO2025088367A1 (en) * | 2023-10-27 | 2025-05-01 | Jodas Expoim Pvt. Ltd | Liposomal composition of idarubicin and cytarabine and process for preparation thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2383259A1 (en) | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
| US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| JP2006508119A (ja) * | 2002-11-06 | 2006-03-09 | ワイス | 急性白血病および骨髄異形成症候群の治療のための組み合わせ療法 |
| US20040152632A1 (en) * | 2002-11-06 | 2004-08-05 | Wyeth | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
| JP2006507324A (ja) * | 2002-11-06 | 2006-03-02 | セルジーン・コーポレーション | 骨髄増殖性疾患を治療および管理するための選択的サイトカイン阻害薬を含む組成物およびその使用法 |
| ES2388064T3 (es) * | 2004-04-22 | 2012-10-08 | Celator Pharmaceuticals, Inc. | Formulaciones liposomales de agentes de antraciclina y análogos de citidina |
| SE0402025D0 (sv) * | 2004-08-13 | 2004-08-13 | Active Biotech Ab | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
| EP1976485A4 (en) | 2005-12-22 | 2011-10-26 | Celator Pharmaceuticals Inc | LIPOSOMAL FORMULATIONS WITH SECONDARY AND TERTIARY AMINES AND METHOD OF MANUFACTURING THEREOF |
-
2008
- 2008-02-15 CA CA2678332A patent/CA2678332C/en active Active
- 2008-02-15 EP EP17200498.8A patent/EP3300601B1/en active Active
- 2008-02-15 CN CN201610324431.2A patent/CN105998046A/zh active Pending
- 2008-02-15 ES ES08730048.9T patent/ES2650167T3/es active Active
- 2008-02-15 DK DK08730048.9T patent/DK2120568T3/en active
- 2008-02-15 HU HUE17200498A patent/HUE058334T2/hu unknown
- 2008-02-15 ES ES17200498T patent/ES2909903T3/es active Active
- 2008-02-15 US US12/032,583 patent/US8092828B2/en active Active
- 2008-02-15 WO PCT/US2008/054168 patent/WO2008101214A2/en not_active Ceased
- 2008-02-15 JP JP2009550160A patent/JP5314600B2/ja active Active
- 2008-02-15 KR KR1020097019393A patent/KR20100014441A/ko not_active Ceased
- 2008-02-15 EP EP08730048.9A patent/EP2120568B1/en not_active Revoked
- 2008-02-15 PL PL08730048T patent/PL2120568T3/pl unknown
- 2008-02-15 PT PT87300489T patent/PT2120568T/pt unknown
- 2008-02-15 DK DK17200498.8T patent/DK3300601T3/da active
- 2008-02-15 SI SI200832194T patent/SI3300601T1/sl unknown
- 2008-02-15 PT PT172004988T patent/PT3300601T/pt unknown
- 2008-02-15 US US12/526,930 patent/US20100303895A1/en not_active Abandoned
- 2008-02-15 KR KR20157007810A patent/KR20150038752A/ko not_active Ceased
- 2008-02-15 AU AU2008216083A patent/AU2008216083B2/en active Active
- 2008-02-15 HR HRP20220428TT patent/HRP20220428T3/hr unknown
- 2008-02-15 PL PL17200498T patent/PL3300601T3/pl unknown
- 2008-02-15 NO NO08730048A patent/NO2120568T3/no unknown
- 2008-02-15 EP EP22150734.6A patent/EP4046640A1/en active Pending
-
2017
- 2017-11-29 CY CY20171101251T patent/CY1119631T1/el unknown
-
2022
- 2022-06-29 LU LU00271C patent/LUC00271I2/en unknown
- 2022-06-30 NO NO2022027C patent/NO2022027I1/no unknown
- 2022-07-05 FR FR22C1034C patent/FR22C1034I2/fr active Active
- 2022-07-05 NL NL301185C patent/NL301185I2/nl unknown
- 2022-07-07 HU HUS2200032C patent/HUS2200032I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301185I2 (nl) | Combinatie van daunorubicine en cytarabine | |
| NL300960I2 (nl) | Combinatie van daunorubicine en cytarabine | |
| NO2020028I1 (no) | saksagliptin og dapagliflozin | |
| NL301016I1 (nl) | Combinatie van daunorubicine en cytarabine | |
| BRPI0813627A2 (pt) | Peptídio antimicrobiano, composições e métodos de uso | |
| DE602007009504D1 (de) | Ballontrokar | |
| DK2185164T3 (da) | Sammensætning og terapeutisk antitumorvaccine | |
| BRPI0906735A2 (pt) | Terapia de combinação que compreende inibidores de sglt e inibidores de dpp4 | |
| BRPI0906980A2 (pt) | Composição de derivados e maleatados | |
| PT2963031T (pt) | Pró-fármacos de tetrahidrocanabinol, composições compreendendo pró-fármacos de tetrahidrocanabinol e métodos de utilização dos mesmos | |
| BRPI0813725A2 (pt) | Métodos e composições para tratamento de doenças | |
| BRPI0919238A2 (pt) | métodos e composições para o tratamento de câncer | |
| BRPI0807495A2 (pt) | Adjuvantes e métodos de emrpego dos mesmos | |
| IL212199A0 (en) | Hpma- docetaxel or gemcitabine conjugates and uses therefore | |
| BRPI0816428A2 (pt) | Folha de vidro e utilização da folha de vidro | |
| EP2064300A4 (en) | ADHESIVE FABRIC COMPOSITIONS AND RELATED METHODS | |
| BRPI0817269A2 (pt) | Análogos de azacitidina e usos dos mesmos | |
| BRPI0716466A2 (pt) | Tratamento da calda de açúcar | |
| DK2170827T3 (da) | Indolin-2-oner og aza-indolin-2-oner | |
| BRPI0814330A2 (pt) | métodos e kits cirúrgicos | |
| BRPI0821106A2 (pt) | Pró-fármacos de nucleosídeo e usos dos mesmos | |
| BRPI0814876A2 (pt) | Análogos de pirona fosforilados e métodos | |
| BRPI0907561A2 (pt) | Materiais e métodos para aperfeiçoamento da saúde de camarões | |
| EP2066480A4 (en) | FLATED BAMBOO PLATE | |
| BRPI0909189A2 (pt) | combinações sinergísticas de 5'-metiltioadenosina |